Adrenocortical secondary prevention: Difference between revisions
Jump to navigation
Jump to search
Created page with "_NOTOC_ {{CMG}}; {{AR}} {{MAD}} {{Adrenocortical carcinoma secondary prevention}} -Overview- Patients should be followed at 3-month intervals after initial treatment for 2 to..." |
No edit summary |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | |||
{{ | {{Adrenocortical carcinoma}} | ||
{{ | {{CMG}}; {{AE}} {{MAD}} | ||
==Overview== | |||
==Adrenocortical carcinoma secondary prevention== | |||
* Patients should be followed at 3-month intervals after initial treatment for 2 to 3 years. | |||
* Surveillance intervals may be increased to 6 months for the next 5 years. | |||
Surveillance intervals may be increased to 6 months for the next 5 years. | |||
-References | * Surveillance should also include: | ||
{{ | ** [[Cross-sectional]] [[imaging]] of [[chest]], [[abdomen]], and [[pelvis]] | ||
** The use of [[FDG-PET]] for [[lesions]] of an unclear nature | |||
** Laboratory evaluation for [[steroid hormones]] | |||
** Evaluation of side effects is also important in case of [[adjuvant]] [[mitotane]] [[therapy]] | |||
==References== | |||
{{reflist|2}} | |||
Latest revision as of 17:11, 3 October 2017
|
Adrenocortical carcinoma Microchapters |
|
Differentiating Adrenocortical carcinoma from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Study |
|
Adrenocortical secondary prevention On the Web |
|
American Roentgen Ray Society Images of Adrenocortical secondary prevention |
|
Risk calculators and risk factors for Adrenocortical secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohammed Abdelwahed M.D[2]
Overview
Adrenocortical carcinoma secondary prevention
- Patients should be followed at 3-month intervals after initial treatment for 2 to 3 years.
- Surveillance intervals may be increased to 6 months for the next 5 years.
- Surveillance should also include: